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Summary
Efficient cell communication is a prerequisite for the co-
ordinated function of tissues and organs. In vertebrates, this
communication is mediated by a variety of mechanisms,
including the exchange of molecules between cells, and
between cells and the extracellular medium, via membrane
channels made of connexin and pannexin proteins. These
channels are a necessary component of all human tissues.
Here, we review the biological essentials of the connexin
and pannexin families, and the roles of these proteins in
the function of cells which are central to major human dis-
eases. We then discuss how connexins and pannexins par-
ticipate in human pathology, and the clinical perspectives
that this knowledge opens.
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Introduction
Proper adaptation of human tissues and organs to the chan-
ging conditions of the environment and of the milieu in-
térieur, of necessity depends on a communication network
between the component cells, which cross-talk to coordin-
ate and, at times, synchronise their activities [1, 2]. With
evolution, this network has progressively diversified to
form a complex array of cross-talking and to some extent
overlapping cell communication mechanisms [3]. These
mechanisms provide for the neural and hormonal signalling
between distant cells, and for the more local signalling en-
sured by extracellular molecules that either interact with
specific cell receptors, or enter cells equipped with ion-se-
lective channels [4]. It is now appreciated that most cells
are also equipped with connexins and pannexins, which
form channels permeable to a large variety of molecules,
and that either link two adjacent cytoplasms (connexins)
or allow for the communication of cytoplasm with the ex-
tracellular fluid (pannexins and, occasionally, connexins)
[5–7]. The striking evolutionary conservation of these pro-
teins, their constant expression in all living animals, and the
specific phenotypes resulting from their experimental mod-
ulation, indicate that connexins and pannexins are indis-
pensable for the functioning of most vertebrate tissues. The
increasing numbers of human diseases that have been as-
sociated with specific mutations and variants of these pro-
teins, or with their quantitative and distribution changes,
further stress their relevance for the clinic [8–14].
Here, we review the biological essentials of connexins and
pannexins, and the roles these proteins play in the insulin-
producing β-cells of the endocrine pancreas, the renin-pro-
ducing cells of the kidney cortex and the vascular cells of
tumours, three cell types that are central to the pathogenes-
is of major human diseases. We then discuss the evidence
implicating connexins and pannexins in human pathology,
and their potential clinical interest.
The connexins
Twenty connexins (Cx), encoded by as many genes, are ex-
pressed in humans [5, 6]. Most cell types of our body sim-
ultaneously co-express multiple connexin species, in pat-
terns that differ in various cell types owing to the control of
gene transcription by cell-specific promoters [5, 6]. The ex-
pression of the cognate proteins is largely regulated at the
transcriptional level, even though some connexins may fur-
ther undergo a variety of post-translational modifications
[5, 6]. Along the trafficking from the endoplasmic retic-
ulum to the cell membrane, all connexins acquire a similar
membrane topography, featuring four membrane-spanning
domains, linked by two extracellular and one intracellular
loop, and both N- and C-terminal regions in the cytoplasm
(fig. 1a). The amino acid sequence of the four α-helical
trans-membrane domains, the two extracellular loops and
the N-terminus are highly conserved in different mammali-
an species, whereas the sequence of the intracellular loop
and the C-terminus are highly variable [5, 6]. During their
transport within endoplasmic reticulum- and Golgi-derived
vesicles, six connexin molecules, of either the same or
a different type, oligomerise to form a doughnut-shaped
structure referred to as a connexon, which provides the wall
of a central hydrophilic space of 2–3 nm in diameter.
Connexons are usually inserted into lipid rafts of the cell
membrane, wherefrom they diffuse to cluster in regions
where calcium-dependent cell adhesion molecules permit
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the close apposition of the membranes of adjacent cells.
At these sites, the intercellular space is reduced to a “gap”
(hence these sites are referred to as gap junctions) of about
2 nm thickness, where the connexons of two adjacent cells
join, extracellular loop-to-extracellular loop, to form an in-
tercellular, gap junctional channel (fig. 1a) [5, 6]. Through
these channels, adjacent cells rapidly and bi-directionally
exchange a variety of cytosolic molecules, including ions,
metabolites, nucleotides, morphogens, vitamin cofactors,
small peptides and microRNAs (miRNAs), which move
from cell-to-cell (fig. 1c) by diffusion, along electrochem-
ical gradients, without escaping into the extracellular fluid
[5, 6]. This event, which is referred to as ionic and meta-
bolic coupling or cell-to-cell coupling, is controlled by the
Figure 1
Connexins and pannexins. (a) All connexins (blue) feature 4
domains, which cross the cell membrane (grey) and are connected
by one cytoplasmic loop and two extracellular loops. Six connexins
oligomerise to form tubular structures, referred to as connexons.
Connexons of one cell usually pair with the connexons of an
adjacent cell to bridge the intercellular space (asterisks), thus
establishing a cell-to-cell, or gap junctional channel. Infrequently,
connexons may also be inserted in a non-junctional region of the
cell membrane to form “hemi-channels”, which connect cytoplasms
to the extracellular medium. (b) Pannexins (green) show a
membrane topography similar to that of connexins, and also
oligomerise to form pannexons, similar to connexons. However,
pannexins feature glycosylated residues on the second
extracellular loop that prevent the close apposition of two cells,
which is required to form intercellular channels. Hence, pannexons
only form non-junctional channels. (c) Connexins mediate cell-to-
cell communications by allowing for a bidirectional, diffusional
exchange of several cytosolic molecules, including those listed
(blue). Pannexins mediate the efflux of cytosolic molecules (green),
thus allowing for paracrine signalling, or the uptake by the cells of
molecules present in the extracellular medium.
opening and closing of the connexin channels, which are
gated by several factors, including cytosolic pH and free
calcium concentration. The conductance and permeability
of the individual channels is a function of their connexin
composition, and of the size, shape and charge of the per-
meant molecules. Contrasting with many other membrane
proteins, connexins have a rather short half-life. Their
turnover usually involves the invagination of plaques of
gap junction channels into one of the interacting cells,
and their degradation by both the lysosomal and the pro-
teasomal pathways [5, 6].
Connexins have been implicated in many prenatal, neonatal
and adult cell functions, including cell division, apoptosis,
migration, organ growth and morphogenesis during em-
bryogenesis, cell differentiation, gene expression, electrical
and metabolic synchronisation, cell contraction, secretion
of exocrine and endocrine glands, growth and renewal of
normal tissues, resistance of tissues to cytotoxic pharmaco-
logical, immune and infectious agents, immune reactions,
cell transformation, tumour growth and metastasis [5, 6].
The in vivo relevance of these functions is supported by
the specific phenotypes observed in a variety of transgen-
ic models featuring a knock-in, a knock out or a mutation
of selected connexin isoforms [5, 6]. The clinical relevance
of at least some of these phenotypes is stressed by the in-
creasing identification of human diseases which are associ-
ated to mutations and single nucleotide polymorphisms of
specific connexins [5, 6, 8–12]. These studies have further
documented that, if most connexins allow for cell-to-cell
coupling, other functions are dependent on specific con-
nexin isoforms [6, 7]. Most of these functions have been at-
tributed to the connexin-dependent cell coupling. However,
some effects may be intracellular, i.e. accounted for by the
interaction between connexins and other proteins, and/or
their effects on gene expression [5, 6].
Some connexons infrequently remain in non-junctional do-
mains of the cell membrane, where they function as uni-
cellular “hemi-channels” (fig. 1a), for the bi-directional ex-
change of ions and second messengers between cytosol
and the extracellular space (fig. 1c). The biophysical prop-
erties of “hemi-channels” differ from those of the junc-
tional channels made by the same connexin species, sug-
gesting distinct roles. However, whether such roles are
of physiological relevance remains to be assessed, inas-
much as function of connexin hemi-channels has so far
been demonstrated only under pathological conditions [6].
The function of such hemi-channels remains under debate,
since it is difficult to distinguish their contribution from
that of gap junction channels and the non-junctional chan-
nels made of pannexins. Most cell types simultaneously ex-
press gap junction plaques made of connexins and second
messenger-permeated non-junctional channels, made by
pannexins and, occasionally, by connexins (fig. 2a,c,d and
fig. 3a,b,c) [6].
The pannexins
Three pannexins (Panx), encoded by as many genes, are
also expressed in humans [6, 7]. Pannexins also display
four membrane-spanning segments, two extracellular and
one cytoplasmic loop, and feature both N- and C-terminal
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domains within the cytoplasm (fig. 1b) [6, 7]. However,
pannexins do not show sequence homology with connex-
ins, and display consensus sequences for glycosylation on
the second extracellular loop (fig. 1b). Most cell types ex-
press Panx1, in combination with various connexin pat-
terns, whereas the distribution of Panx2 and Panx3 is re-
stricted to selected cell types [6, 7]. During their transport
in the cytoplasm, six pannexins oligomerise to form pan-
nexons, which resemble connexons. However, pannexons
do not usually form cell-to-cell channels, since the extra-
cellular loop glycosylation impedes a sufficiently close ap-
proximation and pairing of the pannexons made by adja-
cent cells [6, 7]. The predominant role of pannexons is to
form channels in non-junctional domains of the cell mem-
brane, which show little selectivity for current-carrying
ions, and provide for the leakage of cytosolic second mes-
sengers, including ATP, glutamate and epoxyeicosatrienoic
acid into the extracellular medium (fig. 1c) [6, 7]. Pannex-
ons also permit the reverse uptake into cells of extracellu-
Figure 2
Cx36 and the insulin-producing β-cells. (a) The most abundant
endocrine cell type of pancreatic islets, named β-cells, are only
coupled by Cx36 channels, and also express Panx2 and Panx1. (b)
Loss of Cx36 increases (upward arrow heads) or decreases
(downward arrow heads) the major characteristics of β-cells
(Cx36-coupled cells are shown in blue), notably insulin secretion
and apoptosis. (c) These alterations are also observed in rodents
and humans when β-cells express the rs3743123 variant of
Cx36.The β-cell changes observed under such conditions mimic
the major defects of type 2 and type 1 diabetes. In vitro, cells
expressing this Cx36 variant are less coupled than cells expressing
comparable levels of the wild type Cx36 form. (d) Loss of Panx2
also results in a decrease of glucose-stimulated insulin secretion
and in an increase of β-cell apoptosis. Reverse transcriptase-
polymerase chain reaction analysis indicates that Panx2 and Panx1
may be co-expressed with Cx36 by individual β-cells, although a
validation of this tentative conclusion awaits the development of
fully specific antibodies against the two pannexin species.
lar and membrane-impermeant molecules (fig. 1c) [8, 9].
Opening of pannexin channels is induced by membrane de-
polarisation, mechanical stress, and activation of puriner-
gic receptors, whereas their closure can be experimentally
induced by a number of drugs that also turn off connexin
channels [6, 7]. Under physiological conditions, pannexons
open frequently but briefly, thereby preventing the dialysis
of vital cell moieties [6, 7].
Pannexin channels have been implicated in several cell
functions [8, 9], including the intercellular propagation of
calcium waves mediated by the release of cytosolic ATP,
which activates metabotropic and ionotropic purinergic re-
ceptors both on the cells that release ATP (autocrine path-
way) and in neighbouring cells (paracrine pathway) [6, 7,
13, 14]. Pannexins also contribute to the immune response,
ischaemia-induced cell death, oxidative stress, cell growth
and tumorigenesis, including in humans [6, 7, 13, 14]. Cir-
cumstantial evidence also indicates intracellular functions
of pannexins, including the homeostasis of intracellular
calcium, the formation of the inflammosome, and the re-
lease of bacterial catabolites [6, 7]. In many cell types,
including those that we discuss in this review, individu-
al cells simultaneously express various pannexins togeth-
Figure 3
Cx40, Cx37, Cx43 and the renin-producing cells. (a) Within the
renal cortex, renin-producing cells (RPC) are coupled by Cx37 and
Cx40 channels, to companion cells and nearby endothelial cells
(EC), and also express Panx3. The smooth muscle cells (SMC,
grey) of the afferent arterioles are coupled by Cx43 channels to
companion cells and to RPC. (b) Loss of Cx40 increases the major
function of RPC, i.e. renin biosynthesis and secretion, resulting in
persistent hypertension. These changes are also observed when
cells express the A96S variant of Cx40 (b), but not after deletion of
Cx37 (c). The alterations in renin secretion observed under such
conditions mimic those observed in most forms of hypertension.
Original article Swiss Med Wkly. 2016;146:w14365
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 3 of 14
er with one (e.g. β-cells) or several different connexin spe-
cies (e.g. renin-producing cells, endothelial cells, smooth
muscle cells) (fig. 2a,c,d and 3a,b,c).
Cx36 and the insulin-producing β-cellsof pancreatic islets
Cx36 gap junctions mediate the electrical coupling of most
pancreatic β-cells within each islet of the rodent and human
pancreas, as indicated by the rhythmic and synchronised
bursts of electrical activity and cytosolic free calcium, and
also provide for the exchange of nucleotides and metabol-
ites between small numbers of β-cells (fig. 2a) [5, 15-17].
Full uncoupling and electrical desynchronisation of β-cells
are observed after either the homologous recombination
of the Gjd2 gene, which encodes Cx36 (fig. 2b), or its
conditional deletion in β-cells [5, 15–17]. Physically and
pharmacologically uncoupled β-cells show decreased ex-
pression of the insulin gene and proinsulin biosynthesis, in-
creased basal release of insulin, and poor to nil glucose-
induced insulin release, as a result of a sustained increase
in free cytosolic calcium. These effects are largely revers-
ible after reaggregation or wash-out of the blocking drugs,
two conditions that also promote the recruitment of secret-
ory and biosynthetically active β-cells. Cx36 expression
increases with the neonatal acquisition by mouse β-cells
of a normal sensitivity to glucose, and is reduced after a
high-fat diet, which induces glucose intolerance. In con-
trast, transgenic mice whose β-cells overexpress the ectop-
ic Cx32 become intolerant to glucose as a result of de-
creased insulin secretion [5, 15–17].
The β-cells of Cx36-null mice lack gap junctions and coup-
ling, demonstrating that, in this system, Cx36 is the only
connexin species forming functional cell-to-cell channels
[15, 16, 18]. The pancreatic islets of these animals do not
release insulin in the normal pulsatile fashion owing to loss
of the normal intercellular synchronisation of the cytoso-
lic calcium transients induced by glucose [15, 16]. These
islets also show increased basal release of insulin [5, 16]
resulting in glucose intolerance of the transgenic animals
(fig. 2a) due to alterations of both first and second phases
of insulin release [18]. The excessive basal secretion is
consistent with the finding that uncoupled β-cells can no
longer be inhibited by hyperpolarising currents generated
in nearby cells [19], and with the prolonged decay in their
off-response once glucose stimulation ceases [5, 16]. The
loss of glucose responsiveness is consistent with the loss
of the calcium oscillations that drive the regular oscillatory
output of insulin during stimulation of insulin release [5,
15–18]. The intolerance to post-prandial glucose levels is
likely due to the in vivo decrease in the oscillations of cir-
culating insulin, which associates with lower amplitude and
longer decay of the first phase of glucose-induced insulin
secretion, as well as with reduced insulin oscillations dur-
ing the second phase. The data indicate that Cx36 occupies
a prominent hierarchical position in the multi-factorial reg-
ulation of insulin dynamics, which is central to glycaemic
control [5, 15–18].
In vivo, loss of Cx36 also sensitises β-cells to pharmaco-
logical and immunological conditions resulting in β-cell
death (fig. 2b), specifically in the presence of the cytokines
that induce apoptosis at the onset of type 1 diabetes [5, 15,
19, 20]. Conversely, transgenic mice overexpressing Cx36
are fully protected against the same insults [5, 15]. Pro-
apoptotic cytokines and oxidised low density lipoprotein
particles reduce the expression of Cx36 via mechanisms
dependent on inducible cAMP early repressor (ICER-1)
and AMP-activated protein kinase (AMPK)- [20, 21], and
Cx36 plays a central role in the oxidative and the endo-
plasmic reticulum stress induced by cytokines [19, 20],
two effects that enhance the mitochondria-dependent apop-
tosis of β-cells. The mechanism underlying the protective
role of Cx36 remains to be unravelled. The data show that
physiological Cx36 signalling contributes to the survival of
β-cells.
Cx36 may also form “hemi-channels” on non-junctional
portions of the β-cell membrane [16] which, by permitting
a leakage of cytosolic molecules into the extra-cellular
islet fluid, may have an autocrine effect on β-cells and/or
a paracrine action on their neighbours. However, there is
as yet no evidence that these channels are opened under
physiological conditions. Beta-cells further express Panx2
and Panx1 [16] (fig. 2a,b,c), which may provide channels
for a glutamate-dependent paracrine pathway. Whether
these proteins form functional channels in pancreatic islets
remains to be shown. Still, pancreatic islets from
Panx2-null mice show a decrease in basal and glucose-in-
duced insulin secretion, and an increase in both basal and
cytokine-induced β-cell apoptosis (fig. 2d). Thus, Panx2
may contribute to autocrine and/or paracrine purinergic
mechanisms involving ADP and P2Y receptors, which
could contribute to control the survival and function of
insulin-producing cells under pathologic conditions, not-
ably in diabetes [16].
Cx40, Cx37 and the renin-producingcells of kidneys
Adult renin-producing cells are coupled to companion
cells, as well as to the nearby endothelial cells of the jux-
taglomerular apparatus, by gap junction channels [5, 22]
made of Cx40 and Cx37 [5, 22] (fig. 3a). This coupling is
implicated in the transmission along the afferent arteriole
of vasomotor signals generated in the macula densa cells,
and also accounts for so-called “nephron coupling” [5, 22].
Invalidation of the Cx40 gene results in a marked and sus-
tained hypertension of mice (fig. 3b), a phenotype largely
explained by an increased synthesis and release of renin
[5, 22]. This increase results from the loss of the normal
feedback mechanisms whereby the circulating levels of an-
giotensin II, as well as an increased intrarenal blood pres-
sure, normally suppress the expression of the renin gene
and the release of the hormone in the afferent arteriole [5,
22]. The inhibitory effect of the macula densa on renin se-
cretion is also attenuated in Cx40-deficient mice [5, 22].
The deletion of Cx40 only in renin-secreting cells induces a
hypertension similar to that of the Cx40-null mice (fig. 3b)
[5, 22], whereas the restoration of Cx40 only in the renin-
secreting cells of the latter animals reduces their renin and
hypertension levels [23]. In contrast, the endothelium-spe-
cific deletion of Cx40 does not alter blood pressure [5,
22], and the restoration of Cx40 expression only in the en-
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dothelial cells of Cx40-null mice fails to reduce their hy-
pertension, in spite of a normal expression of Cx37 and
endothelial nitric oxide synthase (eNOS) [23]. Cx37-null
mice [24], which feature a normal renal expression of
Cx40, Cx43 and Cx45, are normotensive, and show normal
values of renin secretion (fig. 3c), even though this secre-
tion is stimulated by a low salt diet more in these mice
than in control animals [25]. In situ, renin-producing cells
also interact with the smooth muscle cells of the afferent
arterioles, which are coupled by Cx43 [26], and the renal
levels of this protein are increased in both the hypertensive
Cx40-null mice and in control mice made hypertensive by
clipping one renal artery. Even though mice with a smooth
muscle cell-specific deletion of Cx43 are normotensive, the
replacement of Cx43 by Cx32 reduces renin production
and protects mice from the hypertension that is normally
induced by a decrease in the blood supply to one kidney or
by a high-salt diet [26].
The data show the prominent role of Cx40 in the regulation
of renin secretion and, thus, of blood pressure, and also
stress the additional contribution of Cx43. Panx3 has been
reported in the juxtaglomerular apparatus [27], but the pos-
sible involvement of non-junctional connexin and pannexin
channels in renin-dependent hypertension has not yet been
directly evaluated.
Cx40, Cx37, Cx43 and the endothelialand smooth muscle cells of vessels
The hypertension of Cx40-deficient mice is partly accoun-
ted for by peripheral vascular effects of the renin-depend-
ent activation of the renin-angiotensin system [5]. Thus,
Cx40-null mice feature an altered vasomotion of small ar-
terioles, and blockade of either angiotensin converting en-
zyme or the angiotensin II receptor AT1 reduces their hy-
pertension. The obligatory participation of peripheral vas-
cular factors is further supported by the observation that
the replacement of Cx40 by Cx45 induces modest hyper-
tension, in spite of normal levels of plasma renin [22]. The
vascular component of hypertension appears to be a result
of an interruption of the cell-to-cell coupling mediated by
Cx40, which normally controls the vasomotor tone, since
Cx40-null mice feature an abnormal reactivity of the peri-
pheral vasculature [28], variably attributed to the loss of
Cx40, the concurrent decrease of Cx37 [5, 22, 27], or the
up-regulation of Cx43 [29].
The endothelial cells of the afferent arterioles of kidneys,
and of many other extra-renal arteries, are coupled by Cx40
and Cx37 (fig. 4a) [22, 29, 30]. The two connexins tightly
interact with eNOS, increasing the activity of the enzyme
and, thus, the production of NO. In turn, NO promotes the
relaxation of smooth muscle cells, resulting in vasodila-
tion. Accordingly, loss of either Cx40 or Cx37 impairs this
mechanism [22, 30]. In contrast, the interactions of Cx40
and Cx37 with eNOS are increased in a murine model of
volume-dependent hypertension [31]. The implementation
of this model in Cx40-null mice, which represent a ge-
netic model of renin-dependent hypertension, resulted in
a further increase of their native hypertension and eNOS
phosphorylation [31]. The data demonstrate that Cx37 and
Cx40 modulate in vivo the production of NO and, thus, vas-
odilatation. The smooth muscle cells of many arterioles are
coupled by Cx43 and Cx45 channels [5, 22], which ensure
the rapid diffusion along the vascular tree of the calcium-
dependent contraction waves that ultimately control vaso-
motor tone [32]. The Cx43 of smooth muscle cells in-
creases with thickening of the media in different models of
chronic renin-dependent hypertension [29], but not in mod-
els in which hypertension is caused by the pharmacological
inhibition of eNOS. In contrast, all models of chronic hy-
pertension induce Cx37 and increase Cx45 in the smooth
muscle cells of the hypertrophied media layers [22, 29, 31].
The potential contribution of non-junctional connexin and
pannexin channels has not yet been directly investigated in
hypertension models. However, mice lacking Panx1 in vas-
cular smooth muscle cells are hypotensive, suggesting that
Panx1 expression contributes to the development of peri-
pheral resistance [17].
Cx40 and cancer cells andangiogenesis
Angiogenesis is fundamental to the growth of most tu-
mours [33]. During this process, quiescent endothelial cells
Figure 4
Cx40, cancer growth and angiogenesis. (a) In most tissues, the
endothelial cells of micro vessels are coupled (blue) by Cx37 and
Cx40 channels. (b) The tumoral growth of transformed tissues is
usually associated with the proliferation of endothelial cells,
resulting in the excessive development of new vessels, which
feature abnormal walls lacking pericyte (grey cells) coverage. (c)
These alterations, and the growth of transformed cells are
decreased after loss of Cx40, resulting in a prolonged survival of
the tumour-bearing animals. (d) Restoration of Cx40 expression in
endothelial cells, prevents both excessive angiogenesis and tumour
growth.
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migrate and proliferate to form new vessels, which are re-
quired to ensure the oxygenation and feeding of growing
tumours. The newly formed vessels show a disorganised
architecture, with a leaky intima layer and few, abnormal
pericytes (fig. 4c), resulting in haemorrhages and increased
interstitial fluid pressure, which limit blood perfusion [33,
34].
Endothelial cells are coupled by Cx40, Cx37 (fig. 4a) and
Cx43 channels [29]. The latter connexin is also expressed
by the smooth muscle cells and the pericytes of some ves-
sels (fig. 4a,b,c) [35]. In the absence of Cx40, the growth
of melanoma and urogenital model tumours is reduced in
mice, a change associated with a decrease in angiogenes-
is (fig. 4b) and eNOS activity [36]. Under these condi-
tions, newly-formed tumour vessels feature a normal struc-
ture (fig. 4b), providing for an improved perfusion of the
growing tumour, which presumably accounted for the ex-
tended survival of the tumour-bearing animals observed
after cyclophosphamide administration [36]. The data im-
plicate Cx40 in the in vivo production of NO, and the en-
suing regulation of angiogenesis which modulates tumour
growth [36].
The combined invalidation of Cx40 and Cx37 causes lethal
perinatal haemorrhages, indicating that both connexins are
required for the normal development of the microvascu-
lature. Given that both Cx37 and Cx40 directly interact
with eNOS [30, 37], and that the levels of Cx37 expression
are linked to those of Cx40 [30], a partial loss of Cx37 sig-
nalling could contribute to the alterations in tumour growth
and angiogenesis. However, the angiogenesis and tumour
alterations observed in mice lacking Cx40 are prevented in
transgenic mice in which the connexin is solely restored in
the endothelial cells (fig. 4c), and are mimicked in vari-
ous angiogenesis models by a peptide that specifically in-
terferes with Cx40 [36], indicating that this connexin iso-
forms plays a hierarchically predominant role in the control
of both angiogenesis and tumour growth.
This tentative conclusion does not exclude participation of
Cx43. Indeed, mice expressing about 50% of the control
levels of Cx43 show an increased vascularisation of tu-
mours resulting from implanted breast cancer cells, and
still feature decreased mural cell coverage. Low levels of
Cx43 also associate with increased expression of vascular
endothelial growth factor (VEGF) and enhanced prolifer-
ation of endothelial cells in tumours generated by injec-
tion of mice with different types of transformed cells [38].
In contrast, when the same cells overexpressed Cx43, tu-
mour growth and angiogenesis decrease [38]. Thus, Cx43
modulates the wall of neoangiogenetic vessels, whose al-
teration is one of the causes of the hypoxic environment
of tumours, which usually increases their malignant phen-
otype and metastatic potential [35]. No direct experimental
evidence has implicated the non-junctional channels made
by connexins and pannexins in the control of angiogenesis.
In contrast, increasing evidence implicates pannexins in tu-
mour growth and metastasis [13, 14, 39].
The human situation
The observations summarised above provide compelling
evidence that connexins and pannexins significantly con-
tribute to the control of many cell functions in vivo. The
finding that the cell-specific patterns of connexins, pannex-
ins and coupling are remarkably conserved in different spe-
cies, and that the phenotype of mice featuring cell-specific
alterations of connexin/pannexin patterns mimics the signs
of human diseases [5, 9, 10, 15–17, 35, 36], suggest that the
signalling dependent on these proteins may be relevant in
the pathogenesis of common clinical conditions. Specific
polymorphisms and mutations of individual connexins and
pannexins have now been linked to a variety of genetic dis-
eases [8–14, 35, 36], and quantitative alterations in the two
families of proteins have also been implicated in a variety
of other diseases [5–7, 13]. Obviously, these implications
cannot be validated in humans by the direct experimental
testing that is feasible in rodents, and largely rely on ge-
netic analysis of selected populations. In the autoimmune,
type I form of diabetes, type 1 helper T cell (Th1) cytokines
kill most pancreatic β-cells by apoptosis, leaving a residual
mass insufficient to sustain the insulin demand of the or-
ganism. The loss of either Cx36 or Panx2 sensitises β-cells
to the proapoptotic action of cytokines and, conversely, the
overexpression of Cx36 protects against this lethal effect
[5, 15, 19, 20].
Consistent with these findings, Th1 cytokines decrease
Cx36 expression [5, 11, 15, 19, 20], and altered expression
of the Cx36 transcript is detected in genome-wide scans
of type I diabetes models [5, 11]. The phenotype of mice
lacking Cx36 also mimics the β-cell alterations typical of
prediabetes and type 2 diabetes, including loss of circulat-
ing insulin oscillations, glucose intolerance, increased bas-
al secretion, decreased glucose-induced insulin secretion
and increased β-cell apoptosis [5]. The GJD2 gene, which
codes for human Cx36, is on a locus (15q14) that associ-
ates with type 2 diabetes [5, 11, 15, 16]. Hyperglycaem-
ic individuals show lower levels of Cx36 messenger RNA
than normoglycaemic individuals, particularly if they ex-
press the rs3743123 variant of Cx36 (fig. 2c) [11]. This
variant differs from the wild type control Cx36 by a single
nucleotide. In mice, this variant reduces the expression of
Cx36 and the β-cell mass of adult animals, resulting in sus-
tained hyperglycaemia in some, but not all, families [11].
A sulphonylurea, which stimulates insulin release from the
glucose-unresponsive β-cells of type 2 diabetic patients, in-
creases Cx36 coupling [5, 15, 20] and prevents the autoim-
mune apoptosis of β-cells in a model of type 1 diabetes
[40]. Together with the findings that prolonged exposure
of insulin-producing cells to high concentrations of gluc-
ose and fatty acids down regulates Cx36 expression, and
that the levels of Cx36 transcript correlate with those of in-
sulin [5, 15, 16], these observations indicate that reduced
levels of Cx36 could be implicated in the pathogenesis of
diabetes.
In humans, most forms of chronic hypertension result from
altered functioning of the renin-angiotensin system, with or
without alterations in resistance arteries. The distribution of
connexins and pannexins is similar in the kidneys and ves-
sels of humans and rodents, and the phenotype of animals
submitted to the loss of either renal or vascular connexins,
or to experimental models of renin-dependent and -inde-
pendent hypertension, mimics the signs of the correspond-
ing human diseases. On the renal side of the disease, two
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polymorphisms within the promoter region of the human
Cx40 gene reduce the permeability of Cx40 channels and
are associated with hypertension in mice [40] and selected
human populations [5, 41, 42]. One of these polymorph-
isms also significantly increases the standing systolic blood
pressure of normotensive individuals [42]. A mutation of
Cx40 (A96SCx40), which reduces the permeability of the
Cx40 channel, associates with patients suffering from car-
diac arrhythmia and with hypertension in mice [41].
Circumstantial evidence indicates that connexin and pan-
nexin channels are implicated in the establishment, growth
and metastasis of a variety of cancers [13, 14, 17, 38]. Not-
ably, a mutation of Panx1 is enriched in highly metastat-
ic breast cancers, and Panx2 levels may correlate with the
prognosis of glial tumours [17].
The translational perspectives
Figure 5
The translational perspectives. (a) The stimulation (arrows) of
junctional and non-junctional channels (e.g. those formed by Cx36
and Panx2) is expected (dotted lines) to reproduce in humans the
beneficial effects of connexin (blue) and pannexin (green) signalling
observed in rodents. In turn, increasing the function of pancreatic β-
cells is expected to improve the treatment of type 1 or type 2
diabetes. Increased connexin and pannexin signalling is also
expected to foster the integration in the host tissues of surrogate
cells designed for cell replacement therapies. (b) Conversely, the
inhibition (flat-end lines) of selected connexin species (e.g. Cx40) is
expected to prevent the over-stimulation of the renin-producing
cells, thus contributing to mitigate several forms of hypertension.
The specific down-regulation of Cx40 is also expected to prevent
excessive angiogenesis, while preserving a normal vessel wall and
function, thus improving the efficiency of current cytotoxic therapies.
This combined approach could reduce the growth of some cancer
forms and the development of other diseases due to excessive
angiogenesis.
Screening of connexin mutations is now a standard in the
diagnoses of congenital, prelingual deafness [8, 9] and skin
disorders [9, 10].
Clinical trials have begun in which retroviral vectors are
used to express herpes simplex virus thymidine kinase in
tumour cells [43]. The transduced cells can then be killed
in vivo by ganciclovir, a guanosine analogue that, after
phosphorylation by the viral enzyme, blocks cell prolif-
eration by incorporating into nascent DNAs [43]. Strik-
ingly, only a fraction of the transformed cells need to ex-
press the viral kinase to make the whole tumour sensitive
to ganciclovir. Even if the mechanism of this "bystander
effect" (fig. 5) [43] is still debated, the finding that the
ganciclovir metabolite is transferred between infected and
non-infected cells via gap junctional channels, indicates a
likely role of connexin signalling [44]. An analogous, be-
neficial effect is “channel sharing”, whereby ionic fluxes
into only a limited proportion of cells are sufficient to cor-
rect the defective functions of a much larger cell popula-
tion. For example, less than 10% of the cells lacking the
cystic fibrosis transmembrane conductance regulator pro-
tein (CFTR) need to be corrected, by CFTR transduction,
to restore a normal fluid transport of intact epithelial sheets
[45], given that connexin and pannexin channels are per-
meable to chloride anions [5]. Thus connexin and/or pan-
nexin channels can amplify the effects of drugs and the cor-
rection of various genetic defects [46].
The studies reviewed here further demand that connexins
and pannexins be considered in development of innovative
approaches for the treatment of highly prevalent human
diseases, by targeting junctional and non-junctional chan-
nels, using drugs altering the function of specific connexin
and/or pannexins (fig. 5). For example, the antidiabetic
sulphonylurea glibenclamide promotes the biosynthesis
and function of Cx36 channels and is sufficiently safe for
chronic administration in diabetic patients [5, 16]. The mo-
lecule is expected to promote connexin signalling, thus
fostering insulin secretion and decreasing the apoptosis of
pancreatic β-cells. On the other hand, the uricosuric probe-
necid, which blocks with some specificity Panx1 channels,
may help to inhibit cancer growth [13, 14, 17]. It is likely
that molecular tools will be instrumental to the develop-
ment of mimetic peptides, miRNAs, and sense and antisen-
se constructs (fig. 5), which have been shown to selectively
interfere with the production and function of connexons
and pannexons, including in human diseases [6, 47–49].
For example, a non-coding miRNA, which is down-regu-
lated in the early stage of colorectal cancer [47] and acts
as a tumour suppressor, is transferred via gap junctions
between endothelial and transformed cells, limiting tumour
angiogenesis and cancer growth [47]. As yet, however,
few molecules match the obligatory specificity, reversib-
ility and safety criteria required for use in the clinic, re-
quiring the development of novel models for large-scale
screening of better candidates [50]. This novel and most
needed connexin/pannexin pharmacology is expected to
foster the efficacy of existing treatments. For example, the
association of drugs improving Cx36 signalling with drugs
inhibiting the key metabolic enzyme AMPK is anticipated
to improve the effects of the two individual therapies in de-
creasing β-cell apoptosis and in increasing insulin secretion
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[5, 15, 16]. Also, drugs inhibiting Cx40 signalling should
potentiate the effects of a combined cytotoxic treatment, by
favouring the delivery of the drug within tumours, via their
beneficial effects on the structure of the newly formed ves-
sels [48, 49].
The ongoing implementation of cell therapies, in which
surrogate stem, progenitor or induced pluripotent stem cells
are engineered for the in vivo replacement of damaged
cells, implies that the transplanted cells become function-
ally integrated within the host tissue. In turn, this integ-
ration implies an adequate development of connexin- and
pannexin-dependent cell interactions. Most of the em-
bryonic stem cells and progenitor cells that are the basis
of many such trials do not express the connexins found in
adult tissues [5, 16], e.g. Cx36 for islet β-cells, possibly ex-
plaining the limited efficacy of the purported replacement.
Proper expression of specific connexins/pannexins in the
surrogate cells is expected to improve the efficacy of cell
therapies (fig. 5), e.g. for the proper replenishment of β-
cells in diabetic patients [51].
Conclusions
The signalling by connexins and pannexins has taken its
place among the numerous mechanisms that collectively
allow cells to ensure coherent functioning of tissues and or-
gans. The available data point to a relevant role of both pro-
tein families in the physiological regulation of many cells,
which are central to, if not causal of, prominent human dis-
eases. These considerations now call for further research
on the molecular organisation of connexin and pannexin
signalling, on the cellular mechanisms that they activate,
and on their hierarchical relationships. This information is
a prerequisite for testing the pathogenetic role of connexins
and pannexins, which, in turn, is needed to validate the po-
tential usefulness of targeting these proteins for the devel-
opment of innovative therapeutic strategies. In view of the
variety of cell functions in which connexins and pannexins
are involved, and of the complexity of the signalling arrays
to which this signalling contributes in living tissues, these
challenges are both considerable and exciting. Taking up
these challenges is now timely, given the explosive world-
wide prevalence of those human diseases to which connex-
ins and pannexins may contribute, and for the treatment of
which the existing therapies still have little efficiency and
specificity and many secondary effects, and represent a ma-
jor individual and economic burden.
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Figures (large format)
Figure 1
Connexins and pannexins. (a) All connexins (blue) feature 4 domains, which cross the cell membrane (grey) and are connected by one
cytoplasmic loop and two extracellular loops. Six connexins oligomerise to form tubular structures, referred to as connexons. Connexons of one
cell usually pair with the connexons of an adjacent cell to bridge the intercellular space (asterisks), thus establishing a cell-to-cell, or gap
junctional channel. Infrequently, connexons may also be inserted in a non-junctional region of the cell membrane to form “hemi-channels”, which
connect cytoplasms to the extracellular medium. (b) Pannexins (green) show a membrane topography similar to that of connexins, and also
oligomerise to form pannexons, similar to connexons. However, pannexins feature glycosylated residues on the second extracellular loop that
prevent the close apposition of two cells, which is required to form intercellular channels. Hence, pannexons only form non-junctional channels.
(c) Connexins mediate cell-to-cell communications by allowing for a bidirectional, diffusional exchange of several cytosolic molecules, including
those listed (blue). Pannexins mediate the efflux of cytosolic molecules (green), thus allowing for paracrine signalling, or the uptake by the cells
of molecules present in the extracellular medium.
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Figure 2
Cx36 and the insulin-producing β-cells. (a) The most abundant endocrine cell type of pancreatic islets, named β-cells, are only coupled by
Cx36 channels, and also express Panx2 and Panx1. (b) Loss of Cx36 increases (upward arrow heads) or decreases (downward arrow heads)
the major characteristics of β-cells (Cx36-coupled cells are shown in blue), notably insulin secretion and apoptosis. (c) These alterations are
also observed in rodents and humans when β-cells express the rs3743123 variant of Cx36.The β-cell changes observed under such conditions
mimic the major defects of type 2 and type 1 diabetes. In vitro, cells expressing this Cx36 variant are less coupled than cells expressing
comparable levels of the wild type Cx36 form. (d) Loss of Panx2 also results in a decrease of glucose-stimulated insulin secretion and in an
increase of β-cell apoptosis. Reverse transcriptase-polymerase chain reaction analysis indicates that Panx2 and Panx1 may be co-expressed
with Cx36 by individual β-cells, although a validation of this tentative conclusion awaits the development of fully specific antibodies against the
two pannexin species.
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Figure 3
Cx40, Cx37, Cx43 and the renin-producing cells. (a) Within the renal cortex, renin-producing cells (RPC) are coupled by Cx37 and Cx40
channels, to companion cells and nearby endothelial cells (EC), and also express Panx3. The smooth muscle cells (SMC, grey) of the afferent
arterioles are coupled by Cx43 channels to companion cells and to RPC. (b) Loss of Cx40 increases the major function of RPC, i.e. renin
biosynthesis and secretion, resulting in persistent hypertension. These changes are also observed when cells express the A96S variant of Cx40
(b), but not after deletion of Cx37 (c). The alterations in renin secretion observed under such conditions mimic those observed in most forms of
hypertension.
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Figure 4
Cx40, cancer growth and angiogenesis. (a) In most tissues, the endothelial cells of micro vessels are coupled (blue) by Cx37 and Cx40
channels. (b) The tumoral growth of transformed tissues is usually associated with the proliferation of endothelial cells, resulting in the excessive
development of new vessels, which feature abnormal walls lacking pericyte (grey cells) coverage. (c) These alterations, and the growth of
transformed cells are decreased after loss of Cx40, resulting in a prolonged survival of the tumour-bearing animals. (d) Restoration of Cx40
expression in endothelial cells, prevents both excessive angiogenesis and tumour growth.
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Figure 5
The translational perspectives. (a) The stimulation (arrows) of junctional and non-junctional channels (e.g. those formed by Cx36 and Panx2)
is expected (dotted lines) to reproduce in humans the beneficial effects of connexin (blue) and pannexin (green) signalling observed in rodents.
In turn, increasing the function of pancreatic β-cells is expected to improve the treatment of type 1 or type 2 diabetes. Increased connexin and
pannexin signalling is also expected to foster the integration in the host tissues of surrogate cells designed for cell replacement therapies. (b)
Conversely, the inhibition (flat-end lines) of selected connexin species (e.g. Cx40) is expected to prevent the over-stimulation of the renin-
producing cells, thus contributing to mitigate several forms of hypertension. The specific down-regulation of Cx40 is also expected to prevent
excessive angiogenesis, while preserving a normal vessel wall and function, thus improving the efficiency of current cytotoxic therapies. This
combined approach could reduce the growth of some cancer forms and the development of other diseases due to excessive angiogenesis.
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